NURIX THERAPEUTICS, INC. Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss
NURIX THERAPEUTICS, INC. (NRIX) reported Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss of $0 for the 3-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2026-05-31 was $0.00.
- NURIX THERAPEUTICS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2026-02-28 was $0.00.
- NURIX THERAPEUTICS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-05-31 was $0.00.
- NURIX THERAPEUTICS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-02-28 was $0.00.
- NURIX THERAPEUTICS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2025 was $0.00.
- NURIX THERAPEUTICS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2024 was $0.00.
- NURIX THERAPEUTICS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was $0.00.
| Period end | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|
| 2026-05-31 | $0.00 10-Q · filed 2026-07-09 | $0.00 10-Q · filed 2026-07-09 | |
| 2026-02-28 | $0.00 10-Q · filed 2026-04-08 | ||
| 2025-11-30 | $0.00 10-K · filed 2026-01-28 | ||
| 2025-05-31 | $0.00 10-Q · filed 2026-07-09 | $0.00 10-Q · filed 2026-07-09 | |
| 2025-02-28 | $0.00 10-Q · filed 2026-04-08 | ||
| 2024-11-30 | $0.00 10-K · filed 2026-01-28 | ||
| 2023-11-30 | $0.00 10-K · filed 2026-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |